Rapid Media Screening (RMS)
Rapid Media Screening is an integrated platform of services that enables companies to develop proprietary culture media formulations.
Rapid Media Screening consists of four distinct stages
1. Feasibility study
2. Know-how transfer & tech support
3. Express delivery of research-grade material
4. Manufacturing of GMP-grade material
1. Feasibility study
Cell culture media are often affected by technical problems with respect to formulation, preparation and use that may lead to an increasing chemical instability of the culture environment. Starting from culture media characterised by unsatisfactory growth supporting capacities – and possibly containing unwanted components or complex additives – we discuss with the users on how to improve their nutrient mixtures to achieve the target application. Typical applications of newly designed media formulations include molecular biology purposes, routine maintenance and cryopreservation, mass cell cultivation with fortified basal media and feeding solutions, advanced fed-batch bioprocesses with corrective solutions to prevent excess catabolite formation and so on.
2. Know-how transfer & tech support
The discussion on technical feasibility is followed by a know-how transfer with respect to the development of culture media formulations. Identifying essential nutrients with their suitable concentrations and optimising the bioavailability of water-unsoluble ingredients is a key aspect to identify the ideal cell culture environment.
3. Express delivery of custom-made culture media (research-grade material)
Newly developed media are prepared according to our fast-track manufacturing know-how that guarantees delivery of the most preferred media formulations within 20 days from the date of order. We manufacture media as liquid concentrates for reconstitution with tissue culture water and sterile filtration prior to use. The lot size ranges from just 3 liters to 2400 liters research-grade material.
4. Manufacturing of GMP-grade material
Research-grade culture media can be manufactured as liquid concentrates under cGMP by our pharma partner companies. Production volume: 100‘000L per single lot.